International audience
-
November 17, 2000 (v1)Journal articleUploaded on: December 4, 2022
-
October 2003 (v1)Journal article
International audience
Uploaded on: December 4, 2022 -
March 1, 2000 (v1)Journal article
International audience
Uploaded on: December 4, 2022 -
April 17, 1998 (v1)Journal article
International audience
Uploaded on: December 4, 2022 -
April 21, 2000 (v1)Journal article
International audience
Uploaded on: December 4, 2022 -
April 14, 2004 (v1)Journal article
International audience
Uploaded on: December 4, 2022 -
April 2001 (v1)Journal article
International audience
Uploaded on: December 4, 2022 -
September 1, 2005 (v1)Journal article
International audience
Uploaded on: December 4, 2022 -
February 1999 (v1)Journal article
International audience
Uploaded on: December 4, 2022 -
July 4, 2005 (v1)Journal article
International audience
Uploaded on: December 4, 2022 -
January 2014 (v1)Journal article
no abstract
Uploaded on: December 4, 2022 -
February 2008 (v1)Journal article
n.a
Uploaded on: December 4, 2022 -
February 2008 (v1)Journal article
International audience
Uploaded on: December 4, 2022 -
2013 (v1)Journal article
Metastatic melanoma remained for decades without any effective treatment and was thus considered as a paradigm of cancer resistance. Recent progress with understanding of the molecular mechanisms underlying melanoma initiation and progression revealed that melanomas are genetically and phenotypically heterogeneous tumors. This recent progress...
Uploaded on: December 4, 2022 -
December 2009 (v1)Journal article
no abstract
Uploaded on: December 4, 2022 -
May 4, 2017 (v1)Journal article
Metastatic melanoma is a deadly form of skin cancer. Extraordinary breakthroughs have been recently achieved in the treatment of the disease,1 leading to objective increase in patient survival. However, early detection of potential dangerous melanocytic lesions remains the best strategy to avoid metastatic dissemination, which is still the main...
Uploaded on: December 4, 2022 -
January 7, 2019 (v1)Journal article
no abstract
Uploaded on: December 4, 2022 -
December 2018 (v1)Journal article
No abstract available
Uploaded on: December 4, 2022 -
December 2020 (v1)Journal article
The clinical benefit of immune checkpoint inhibitory therapy (ICT) in advanced melanomas is limited by primary and acquired resistance. The molecular determinants of the resistance have been extensively studied, but these discoveries have not yet been translated into therapeutic benefits. As such, a paradigm shift in melanoma treatment, to...
Uploaded on: December 4, 2022 -
February 2011 (v1)Journal article
International audience
Uploaded on: December 4, 2022 -
2020 (v1)Journal article
Malignant melanoma is the most deadly form of skin cancer. It originates from melanocytic cells and can also arise at other body sites. Early diagnosis and appropriate medical care offer excellent prognosis with up to 5-year survival rate in more than 95% of all patients. However, long-term survival rate for metastatic melanoma patients remains...
Uploaded on: December 4, 2022